Pulmonx Q2 2024 Earnings Report

Pulmonx EPS Results

• Actual EPS: -$0.39
• Consensus EPS: -$0.41
• Beat/Miss: Beat by +$0.02
• One Year Ago EPS: N/A

Pulmonx Revenue Results

• Actual Revenue: $20.78 million
• Expected Revenue: $20.23 million
• Beat/Miss: Beat by +$550.00 thousand
• YoY Revenue Growth: N/A

Pulmonx Announcement Details

• Quarter: Q2 2024
• Date: 7/31/2024
• Time: N/A

Pulmonx (NASDAQ:LUNG), a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.